Odronextamab
Odronextamab Basic information
- Product Name:
- Odronextamab
- Synonyms:
-
- Odronextamab
- Research Grade Odronextamab(DHC90715)
- Research Grade Odronextamab
- Odronextamab (anti-CD20&CD3)
- CAS:
- 1801338-64-6
- MW:
- 0
- Mol File:
- Mol File
Odronextamab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Odronextamab Usage And Synthesis
Uses
Odronextamab is a stable humanized IgG4 CD20?×?CD3 bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering anti-tumor activity. Odronextamab is expected to be used in oncology research[1].
in vivo
Odronextamab (0.4-1 mg/kg, administered via intraperitoneal injection, single dose) exhibits dose-dependent tumor-suppressive activity in a mouse tumor model[2].
| Animal Model: | Raji cell xenograft tumor mice model[2] |
| Dosage: | 0.04, 0.1, 0.4, 1.0 mg/kg |
| Administration: | Intraperitoneal injection (i.p.) |
| Result: | Treatment at doses of 0.4 or 1 mg/kg in mice resulted in complete tumor suppression. In mice receiving 0.04-0.1 mg/kg concentrations of odronextamab, tumor growth was slowed. |
References
[1] Rajat Bannerji, et al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet H DOI:10.1016/S2352-3026(22)00072-2
[2] Zhu M, et al. Translational findings for odronextamab: From preclinical research to a first-in-human study in patients with CD20+ B-cell malignancies. Clin Transl Sci. 2022 Apr;15(4):954-966. DOI:10.1111/cts.13212
OdronextamabSupplier
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com